| | |
Mark to Market | Manas Chakravarty, Mobis Philipose, Ravi Ananthanarayanan and Vatsala Kamat 10:21 PM | October 29,2009
Glenmark raised around Rs400 crore through an equity issue in September, which has been used to reduce debt
|
|
Ravi Ananthanarayanan 09:57 PM | October 04,2009
The IPO gives GlenmarkGenerics a market-determined valuation, and is using a large portion of the proceeds to meet some of its obligations arising from the spin-off Glenmark Pharmaceuticals
|
|
PTI 06:40 PM | September 25,2009
The company registered a growth of 18% in overall business in the first quarter
|
|
PTI 11:02 AM | September 15,2009
The proceeds from the issue will be used for covering the company’s debt
|
|
C.H. Unnikrishnan 11:56 PM | September 10,2009
Firm to take on rivals by launching versions of top-selling drugs, to address both chronic and infectious diseases
|
|
Khushboo Narayan and C.H. Unnikrishnan 12:36 AM | September 07,2009
Barring the top 300 pharma firms, most of the 15,000 drug units operating in India are engaged in contract manufacturing
|
|
Radhieka Pandeya 10:08 PM | August 19,2009
The company’s lead respiratory disease molecule oglemilast could not clear phase II of clinical trials
|
|
11:47 PM | July 01,2009
The government needs to make radical changes if it wants India to remain a major player in the global pharmaceutical industry
|
|
Radhieka Pandeya 11:42 PM | April 01,2009
Glenmark Pharmaceuticals Ltd said it will stop selling its morphine sulfate drug in the US, complying with a warning by that country’s drugs regulator
|
|
C.H. Unnikrishnan and Radhieka Pandeya 01:11 AM | February 24,2009
Glenn Saldanha, CEO Glenmark Pharmaceuticals, says all that the company needs is a couple of R&D deals to bring back investor confidence
|
|
C.H. Unnikrishnan and Ashwin Ramarathinam 12:09 AM | February 09,2009
It has been the worst performance in 12 quarters mainly due to currency fluctuations and weak capital market
|
|
PTI 04:13 PM | January 27,2009
The drug major had a consolidated net profit of Rs280 crore in the December quarter last fiscal
|
|
Reuters 03:22 PM | January 23,2009
The molecule is being developed to treat neuropathic pain, osteoarthritic pain and other inflammatory conditions
|
|
Radhieka Pandeya 11:56 PM | December 23,2008
New guidelines require companies to prove that their therapies do not increase cardiovascular risks
|
|
PTI 02:14 PM | November 06,2008
Glenmark Generics’s current portfolio in Europe consist of two approved products and eight marketing authorisation applications
|
|